Published in Clin Exp Immunol on July 01, 1988
Soluble cytokine receptors are present in normal human urine. J Exp Med (1989) 2.24
The extracellular regulation of growth factor action. Mol Biol Cell (1992) 1.25
Molecular basis of the membrane-anchored and two soluble isoforms of the human interleukin 5 receptor alpha subunit. Proc Natl Acad Sci U S A (1992) 1.16
Plasma interleukin-2 and a soluble/shed interleukin-2 receptor in serum of patients with Crohn's disease. Effect of cyclosporin. Gut (1990) 1.06
Metabolism of Tac (IL2Ralpha): physiology of cell surface shedding and renal catabolism, and suppression of catabolism by antibody binding. J Exp Med (1996) 1.03
A disturbance of the IL-2/IL-2 receptor system parallels the activity of multiple myeloma. Clin Exp Immunol (1991) 0.90
Urinary excretion of CD23 antigen in normal individuals and patients with chronic lymphocytic leukaemia (CLL) Clin Exp Immunol (1991) 0.88
Increased excretion of soluble interleukin 2 receptors and free light chain immunoglobulins in the urine of patients with active lupus nephritis. Ann Rheum Dis (1992) 0.84
Evaluation of soluble IL-6 receptor concentration in serum and epithelial lining fluid from patients with interstitial lung diseases. Clin Exp Immunol (1995) 0.83
Pitfalls in the measurement of soluble forms of cell surface receptors. Clin Exp Immunol (1993) 0.75
A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells. I. Production of anti-Tac monoclonal antibody and distribution of Tac (+) cells. J Immunol (1981) 10.92
Adult T-cell leukemia: clinical and hematologic features of 16 cases. Blood (1977) 10.69
T cell growth factor receptors. Quantitation, specificity, and biological relevance. J Exp Med (1981) 10.66
Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med (1985) 8.21
Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro. J Immunol (1985) 5.70
Demonstration of a non-Tac peptide that binds interleukin 2: a potential participant in a multichain interleukin 2 receptor complex. Proc Natl Acad Sci U S A (1986) 4.61
Interleukin 2 high-affinity receptor expression requires two distinct binding proteins. J Exp Med (1987) 4.53
Novel interleukin-2 receptor subunit detected by cross-linking under high-affinity conditions. Science (1986) 4.30
Expression of interleukin 2 receptors on activated human B cells. J Exp Med (1984) 3.27
A monoclonal antibody 7G7/B6, binds to an epitope on the human interleukin-2 (IL-2) receptor that is distinct from that recognized by IL-2 or anti-Tac. Hybridoma (1985) 2.41
The released interleukin 2 receptor binds interleukin 2 efficiently. J Immunol (1986) 2.08
Expression of functional IL 2 receptors by lipopolysaccharide and interferon-gamma stimulated human monocytes. J Immunol (1987) 1.96
Expression of interleukin 2 receptors and binding of interleukin 2 by gamma interferon-induced human leukemic and normal monocytic cells. J Exp Med (1985) 1.87
Uromodulin (Tamm-Horsfall glycoprotein): a renal ligand for lymphokines. Science (1987) 1.60
Uromodulin: a unique 85-kilodalton immunosuppressive glycoprotein isolated from urine of pregnant women. Science (1985) 1.60
A thymocyte-activating factor derived from glomerular mesangial cells. J Immunol (1983) 1.59
An analysis of the cellular requirements for the production of soluble interleukin-2 receptors in vitro. J Clin Immunol (1986) 1.33
Interleukin 2 receptors on cultured murine epidermal Langerhans cells. J Immunol (1986) 1.16
Uromodulin. An immunosuppressive 85-kilodalton glycoprotein isolated from human pregnancy urine is a high affinity ligand for recombinant interleukin 1 alpha. J Biol Chem (1986) 1.11
Stimulation of oligodendroglial proliferation and maturation by interleukin-2. Nature (1986) 1.04
Kinetics, competition, and selectivity of tubular absorption of proteins. Am J Physiol (1982) 0.96
Automated high-performance immunosorbent assay for recombinant leukocyte A interferon. J Chromatogr (1985) 0.80
Initial sequencing and analysis of the human genome. Nature (2001) 212.86
The genome sequence of Drosophila melanogaster. Science (2000) 74.32
Absence of expression of the FMR-1 gene in fragile X syndrome. Cell (1991) 7.04
Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro. J Immunol (1985) 5.70
Rapid isolation of DNA probes within specific chromosome regions by interspersed repetitive sequence polymerase chain reaction. Genomics (1990) 4.34
DNA methylation represses FMR-1 transcription in fragile X syndrome. Hum Mol Genet (1992) 4.22
Human cytotoxic response in vitro to trinitrophenyl-modified autologous cells. I. T cell recognition of TNP in association with widely shared antigens. J Immunol (1978) 3.90
Origin of proteins in sporulation. Annu Rev Biochem (1968) 3.86
Genomic rearrangement in NEMO impairs NF-kappaB activation and is a cause of incontinentia pigmenti. The International Incontinentia Pigmenti (IP) Consortium. Nature (2000) 3.61
Hemagglutinin-specific enzyme-linked immunosorbent assay for antibodies to influenza A and B viruses. J Clin Microbiol (1981) 3.46
Magnesium transport in Escherichia coli. Inhibition by cobaltous ion. J Biol Chem (1971) 3.43
Triplet repeat mutations in human disease. Science (1992) 3.35
A mutation in human CMP-sialic acid hydroxylase occurred after the Homo-Pan divergence. Proc Natl Acad Sci U S A (1998) 3.26
Length of uninterrupted CGG repeats determines instability in the FMR1 gene. Nat Genet (1994) 3.22
Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. Proc Natl Acad Sci U S A (2001) 2.95
Deletion of FMR1 in Purkinje cells enhances parallel fiber LTD, enlarges spines, and attenuates cerebellar eyelid conditioning in Fragile X syndrome. Neuron (2005) 2.82
The human mid-size neurofilament subunit: a repeated protein sequence and the relationship of its gene to the intermediate filament gene family. EMBO J (1987) 2.72
Cytotoxic activities of gut mucosal lymphoid cells in guinea pigs. J Immunol (1978) 2.70
Tissue specific expression of FMR-1 provides evidence for a functional role in fragile X syndrome. Nat Genet (1993) 2.69
The effector cells in human peripheral blood mediating mitogen-induced cellular cytotoxicity and antibody-dependent cellular cytotoxicity. J Immunol (1976) 2.65
The Lowe's oculocerebrorenal syndrome gene encodes a protein highly homologous to inositol polyphosphate-5-phosphatase. Nature (1992) 2.64
X-linked situs abnormalities result from mutations in ZIC3. Nat Genet (1997) 2.62
Secretory and systemic immunological response in children infected with live attenuated influenza A virus vaccines. Infect Immun (1982) 2.61
Large expansion of the ATTCT pentanucleotide repeat in spinocerebellar ataxia type 10. Nat Genet (2000) 2.60
A monoclonal antibody 7G7/B6, binds to an epitope on the human interleukin-2 (IL-2) receptor that is distinct from that recognized by IL-2 or anti-Tac. Hybridoma (1985) 2.41
The soluble interleukin-2 receptor: biology, function, and clinical application. Ann Intern Med (1990) 2.34
The Sézary syndrome: a malignant proliferation of helper T cells. J Clin Invest (1976) 2.32
Isolation of a GCC repeat showing expansion in FRAXF, a fragile site distal to FRAXA and FRAXE. Nat Genet (1994) 2.19
(Over)correction of FMR1 deficiency with YAC transgenics: behavioral and physical features. Hum Mol Genet (2000) 2.17
Cloning of human and bovine homologs of SNF2/SWI2: a global activator of transcription in yeast S. cerevisiae. Nucleic Acids Res (1992) 2.14
Atypical glandular cells of undetermined significance. Diagnostic accuracy and interobserver variability using select cytologic criteria. Am J Clin Pathol (1997) 2.12
The released interleukin 2 receptor binds interleukin 2 efficiently. J Immunol (1986) 2.08
Transport of magnesium by a repressible and a nonrepressible system in Escherichia coli. Proc Natl Acad Sci U S A (1972) 2.04
Multiple pathogenic and benign genomic rearrangements occur at a 35 kb duplication involving the NEMO and LAGE2 genes. Hum Mol Genet (2001) 2.00
Radioimmunotherapy of interleukin-2R alpha-expressing adult T-cell leukemia with Yttrium-90-labeled anti-Tac. Blood (1995) 1.99
Limiting dilution analysis of Epstein-Barr virus-induced immunoglobulin production by human B cells. J Exp Med (1983) 1.97
Expression of functional IL 2 receptors by lipopolysaccharide and interferon-gamma stimulated human monocytes. J Immunol (1987) 1.96
Human and murine FMR-1: alternative splicing and translational initiation downstream of the CGG-repeat. Nat Genet (1993) 1.95
Biochemical studies of bacterial sporulation and germination. 18. Free amino acids in spores. J Biol Chem (1970) 1.94
Duplication of a gene-rich cluster between 16p11.1 and Xq28: a novel pericentromeric-directed mechanism for paralogous genome evolution. Hum Mol Genet (1996) 1.93
Transactivation of interleukin 2 and its receptor induces immune activation in human T-cell lymphotropic virus type I-associated myelopathy: pathogenic implications and a rationale for immunotherapy. Proc Natl Acad Sci U S A (1990) 1.93
Advances in molecular analysis of fragile X syndrome. JAMA (1994) 1.91
Biochemical studies of bacterial sporulation and germination. XII. A sulfonic acid as a major sulfur compound of Bacillus subtilis spores. J Bacteriol (1969) 1.89
Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacology (2001) 1.88
Studies of the expression of the Wiskott-Aldrich syndrome protein. J Clin Invest (1996) 1.87
Virus specificity of human influenza virus-immune cytotoxic T cells. J Immunol (1979) 1.83
Biochemical studies of bacterial sporulation and germination. XIX. Phosphate metabolism during sporulation. J Biol Chem (1970) 1.82
Biochemical studies of the excitable membrane of Paramecium tetraurelia. III. Proteins of cilia and ciliary membranes. J Cell Biol (1980) 1.78
Discrimination of multiple [3H]5-hydroxytryptamine binding sites by the neuroleptic spiperone in rat brain. J Neurochem (1981) 1.75
Direct inhibition of Bruton's tyrosine kinase by IBtk, a Btk-binding protein. Nat Immunol (2001) 1.74
Measuring job stressors and strains: where we have been, where we are, and where we need to go. J Occup Health Psychol (1998) 1.73
Interchromosomal duplications of the adrenoleukodystrophy locus: a phenomenon of pericentromeric plasticity. Hum Mol Genet (1997) 1.70
Cdc42-interacting protein 4 mediates binding of the Wiskott-Aldrich syndrome protein to microtubules. J Biol Chem (2000) 1.63
Pentoxifylline suppression of tumor necrosis factor gene transcription. Surgery (1991) 1.62
Pharmacokinetics of midazolam administered by continuous intravenous infusion to intensive care patients. Crit Care Med (1992) 1.58
Atypical forms of incontinentia pigmenti in male individuals result from mutations of a cytosine tract in exon 10 of NEMO (IKK-gamma). Am J Hum Genet (2001) 1.54
Analysis of immunoglobulin G antibody responses after administration of live and inactivated influenza A vaccine indicates that nasal wash immunoglobulin G is a transudate from serum. J Clin Microbiol (1987) 1.53
Identification of FMR2, a novel gene associated with the FRAXE CCG repeat and CpG island. Nat Genet (1996) 1.52
Elevated Fmr1 mRNA levels and reduced protein expression in a mouse model with an unmethylated Fragile X full mutation. Exp Cell Res (2006) 1.47
Pharmacokinetics of oral and intravenous rifampicin during chronic administration. Klin Wochenschr (1985) 1.46
Interruptions in the triplet repeats of SCA1 and FRAXA reduce the propensity and complexity of slipped strand DNA (S-DNA) formation. Biochemistry (1998) 1.46
Fc receptors on human T-lymphocytes. III. Characterization of subpopulations involved in cell-mediated lympholysis and antibody-dependent cellular cytotoxicity. J Immunol (1979) 1.44
Distinct interactions of the X-linked lymphoproliferative syndrome gene product SAP with cytoplasmic domains of members of the CD2 receptor family. Clin Immunol (2001) 1.44
Heart rate, activity, duration, and affect in added-purpose versus single-purpose jumping activities. Am J Occup Ther (1989) 1.43
Activated lymphocytes during acute Epstein-Barr virus infection. J Immunol (1987) 1.42
High resolution methylation analysis of the FMR1 gene trinucleotide repeat region in fragile X syndrome. Hum Mol Genet (1993) 1.42
Treatment with recombinant human tumor necrosis factor-alpha protects rats against the lethality, hypotension, and hypothermia of gram-negative sepsis. J Clin Invest (1991) 1.41
Haplotypes at ATM identify coding-sequence variation and indicate a region of extensive linkage disequilibrium. Am J Hum Genet (2000) 1.41
Secretory component deficiency. A disorder of the IgA immune system. N Engl J Med (1976) 1.41
Occupationally embedded exercise versus rote exercise: a choice between occupational forms by elderly nursing home residents. Am J Occup Ther (1995) 1.39
Molecular definition of pericentric inversion breakpoints occurring during the evolution of humans and chimpanzees. Genomics (1998) 1.39
Elevated concentrations of soluble interleukin-2 receptors in serum samples and bronchoalveolar lavage fluids in active sarcoidosis. Am Rev Respir Dis (1988) 1.38
Chronic granulomatous disease in females. N Engl J Med (1970) 1.38
The human interleukin-2 receptor: normal and abnormal expression in T cells and in leukemias induced by the human T-lymphotropic retroviruses. Ann Intern Med (1986) 1.37
Comparative genomic sequence analysis of the FXR gene family: FMR1, FXR1, and FXR2. Genomics (2001) 1.35
The generation of a conditional Fmr1 knock out mouse model to study Fmrp function in vivo. Neurobiol Dis (2005) 1.34
An analysis of the cellular requirements for the production of soluble interleukin-2 receptors in vitro. J Clin Immunol (1986) 1.33
Intragenic loss of function mutations demonstrate the primary role of FMR1 in fragile X syndrome. Nat Genet (1995) 1.32
Somatic mosaicism in Wiskott--Aldrich syndrome suggests in vivo reversion by a DNA slippage mechanism. Proc Natl Acad Sci U S A (2001) 1.31
The gene encoding the VP16-accessory protein HCF (HCFC1) resides in human Xq28 and is highly expressed in fetal tissues and the adult kidney. Genomics (1995) 1.31
Fine structure of the human FMR1 gene. Hum Mol Genet (1993) 1.30
Clinical management of keratoconus. A multicenter analysis. Ophthalmology (1990) 1.29
Omeprazole inhibits oxidative drug metabolism. Studies with diazepam and phenytoin in vivo and 7-ethoxycoumarin in vitro. Gastroenterology (1985) 1.29
Selection against mutant alleles in blood leukocytes is a consistent feature in Incontinentia Pigmenti type 2. Hum Mol Genet (1996) 1.28
Differential regulation of Paramecium ciliary motility by cAMP and cGMP. J Cell Biol (1988) 1.28
Haplotype and interspersion analysis of the FMR1 CGG repeat identifies two different mutational pathways for the origin of the fragile X syndrome. Hum Mol Genet (1996) 1.27
Choroid plexus protects cerebrospinal fluid against toxic metals. FASEB J (1991) 1.27
Development of fluorine-18-labeled 5-HT1A antagonists. J Med Chem (1999) 1.27
Molecular and phenotypic variation in patients with severe Hunter syndrome. Hum Mol Genet (1997) 1.26
Spontaneous cell-mediated cytotoxicity by human peripheral blood lymphocytes in vitro. J Immunol (1977) 1.24
Identification and modification of environmental noise in an ICU setting. Chest (1998) 1.23